{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:29:26Z","timestamp":1787016566166,"version":"build-2736575974"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    New, stable, highly water-soluble, nontoxic polysaccharide conjugates of amphotericin B (AmB) are described. AmB was conjugated by a Schiff-base reaction with oxidized arabinogalactan (AG). AG is a highly branched natural polysaccharide with unusual water solubility (70% in water). A high yield of active AmB was obtained with the conjugates which were similarly highly water soluble and which could be appropriately formulated for injection. They showed comparable MICs for\n                    <jats:italic>Candida albicans<\/jats:italic>\n                    and\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    (MICs, 0.1 to 0.2 \u03bcg\/ml). The reduced AmB conjugate, which was synthesized at pH 11 for 48 h at 37\u00b0C, was nonhemolytic and was much safer than conventional micellar AmB-deoxycholate. It was the least toxic AmB-AG conjugate among those tested with mice (maximal tolerated dose, 50 mg\/kg of body weight), and histopathology indicated no damage to the liver or kidneys. This conjugate, similarly to the liposomal formulation (AmBisome), was more effective than AmB-deoxycholate in prolonging survival. It was more effective than both the liposomal and the deoxycholate formulations in eradicating yeast cells from target organs. The overall results suggest that after further development of the AmB-AG conjugate, it may be a potent agent in the treatment of fungal infections.\n                  <\/jats:p>","DOI":"10.1128\/aac.43.8.1975","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T20:35:20Z","timestamp":1539030920000},"page":"1975-1981","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":82,"title":["A Novel Injectable Water-Soluble Amphotericin B-Arabinogalactan Conjugate"],"prefix":"10.1128","volume":"43","author":[{"given":"Rama","family":"Falk","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Clinical Microbiology and Infectious Diseases, The Hebrew University-Hadassah Medical Center,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J.","family":"Domb","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Department of Medicinal Chemistry, The Hebrew University of Jerusalem-School of Pharmacy,2 Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhack","family":"Polacheck","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Clinical Microbiology and Infectious Diseases, The Hebrew University-Hadassah Medical Center,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"544","article-title":"Arabinogalactan\u2014a review of the literature.","volume":"46","author":"Adams M. F.","year":"1963","unstructured":"Adams M. F. Douglas C. Arabinogalactan\u2014a review of the literature. TAPPI J. 46 1963 544 558","journal-title":"TAPPI J."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.4.615"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0147-0272(77)80007-X","article-title":"Infectious complications in the cancer patient.","volume":"1","author":"Bodey G. P.","year":"1977","unstructured":"Bodey G. P. Infectious complications in the cancer patient. Curr. Probl. Cancer 1 1977 1 63","journal-title":"Curr. Probl. Cancer"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.4.512"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.2.294"},{"key":"e_1_3_2_7_2","first-page":"127","article-title":"Pharmacology, toxicity, and therapeutic usefulness of amphotericin B.","volume":"195","author":"Buler W. T.","year":"1966","unstructured":"Buler W. T. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. JAMA 195 1966 127 131","journal-title":"JAMA"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600780409"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/28.suppl_B.1","article-title":"Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host.","volume":"28","author":"Denning D. W.","year":"1991","unstructured":"Denning D. W. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J. Antimicrob. Chemother. 28 (Suppl. B) 1991 1 16","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_10_2","first-page":"1229","article-title":"Nystatin-dextran conjugates: synthesis and characterization.","volume":"34","author":"Domb A. J.","year":"1996","unstructured":"Domb A. J. Linden G. Polacheck I. Benita S. Nystatin-dextran conjugates: synthesis and characterization. J. Polymer Sci. 34 1996 1229 1236","journal-title":"J. Polymer Sci."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.2042-7158.1988.tb05260.x","article-title":"Toxicity of solubilized and colloidal amphotericin B formulation to human erythrocytes.","volume":"40","author":"Foster D.","year":"1988","unstructured":"Foster D. Washington C. Davis S. S. Toxicity of solubilized and colloidal amphotericin B formulation to human erythrocytes. J. Pharm. Pharmacol. 40 1988 325 328","journal-title":"J. Pharm. Pharmacol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/145.2.748","article-title":"Treatment of murine cryptococcosis with liposome-associated amphotericin B.","volume":"145","author":"Graybill J. R.","year":"1982","unstructured":"Graybill J. R. Craven P. C. Taylor R. L. Williams D. M. Magee W. E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145 1982 748 752","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1875-9114.1998.tb03118.x","article-title":"Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients.","volume":"18","author":"Gubbins P. O.","year":"1998","unstructured":"Gubbins P. O. Bowman J. L. Penzak S. R. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients. Pharmacotherapy 18 1998 549 564","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-4453(94)95956-0","article-title":"Liposomal amphotericin B, AmBisome.","volume":"1","author":"Hay R. J.","year":"1994","unstructured":"Hay R. J. Liposomal amphotericin B, AmBisome. J. Infect. 1 1994 35 43","journal-title":"J. Infect."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions.","volume":"22","author":"Hiemenz J. W.","year":"1996","unstructured":"Hiemenz J. W. Walsh T. J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 (Suppl. 2) 1996 S133 S144","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1128\/AAC.36.12.2656","article-title":"Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.","volume":"36","author":"Hostetler J. S.","year":"1992","unstructured":"Hostetler J. S. Clemons K. V. Hanson L. H. Stevens D. A. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36 1992 2556 2560","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_18_2","unstructured":"Larsen C. Dextran products Physico-chemical and chemical aspects in relation to in vivo properties. Ph.D. dissertation. 1990 Villadsen and Christensen Copenhagen Denmark"},{"key":"e_1_3_2_19_2","first-page":"202","article-title":"Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis.","volume":"31","author":"Levy M. Y.","year":"1993","unstructured":"Levy M. Y. Polacheck I. Barenholz Y. Benita S. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis. J. Med. Vet. Mycol. 31 1993 202 218","journal-title":"J. Med. Vet. Mycol."},{"key":"e_1_3_2_20_2","first-page":"81","article-title":"Study of some physicochemical and enzyme properties of polymer derivatives of terrilytin on the basis of dextran.","volume":"11","author":"Lindenbaum G.","year":"1977","unstructured":"Lindenbaum G. Mirgorodskaya O. Moskvichev B. Tereshin I. Study of some physicochemical and enzyme properties of polymer derivatives of terrilytin on the basis of dextran. Khim.-Pharm. Zh. 11 1977 81 86","journal-title":"Khim.-Pharm. Zh."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808001400303"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/bc00030a007","article-title":"Psoralen-containing vinyl monomers for conjugation of double-helical DNA with vinyl polymers.","volume":"5","author":"Maeda M.","year":"1994","unstructured":"Maeda M. Nishimura C. Umeno D. Takagi M. Psoralen-containing vinyl monomers for conjugation of double-helical DNA with vinyl polymers. Bioconj. Chem. 5 1994 527 531","journal-title":"Bioconj. Chem."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/infdis\/158.5.1046","article-title":"Diagnosis and successful treatment of fusariosis in the compromised host.","volume":"158","author":"Merz W. G.","year":"1988","unstructured":"Merz W. G. Karp J. E. Hoagland M. Jett-Goheen M. Junkins J. M. Hood A. F. Diagnosis and successful treatment of fusariosis in the compromised host. J. Infect. Dis. 158 1988 1046 1055","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_24_2","unstructured":"National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. 1997 National Committee for Clinical Laboratory Standards Wayne Pa"},{"key":"e_1_3_2_25_2","unstructured":"Odds F. C. Candida and candidosis 2nd ed. 1988 Bailliere Tindall London United Kingdom"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005020-00003"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0163-4453(94)95971-4","article-title":"Overview of amphotericin B colloidal dispersion (Amphocil).","volume":"28","author":"Stevens D. A.","year":"1994","unstructured":"Stevens D. A. Overview of amphotericin B colloidal dispersion (Amphocil). J. Infect. 28 (Suppl. 1) 1994 45 49","journal-title":"J. Infect."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jac\/32.5.723","article-title":"Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.","volume":"32","author":"van Etten E. W. M.","year":"1993","unstructured":"van Etten E. W. M. van den Heuvel de Groot C. Bakker-Woudenberg I. A. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32 1993 723 739","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_29_2","unstructured":"Zar J. H. Testing for goodness of fit Biostatistical analysis. 1984 40 60 Prentice-Hall Englewood Cliffs N.J"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.8.1975","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.8.1975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:38:51Z","timestamp":1720658331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.8.1975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["10.1128\/AAC.43.8.1975"],"URL":"https:\/\/doi.org\/10.1128\/aac.43.8.1975","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]},"assertion":[{"value":"1998-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-05-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}